Core Viewpoint - The company, Sinovac Biotech (688136.SH), has submitted an application for issuing H-shares and listing on the Hong Kong Stock Exchange on November 6, 2025 [1] Group 1 - The application materials were published on the Hong Kong Stock Exchange website on the same day [1] - The materials were prepared in accordance with the requirements of the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange [1] - The information contained in the application is a draft version and may be updated or revised in due course [1]

Core Insights - Kexing Biopharmaceutical Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Jinshi International as the sole sponsor [1] - The company is an innovative and internationally developed biopharmaceutical firm, focusing on the research, production, and commercialization of recombinant proteins, antibodies, and targeted delivery therapies [1] - Kexing is one of the earliest established biopharmaceutical companies in China and is a key industrialization base for the national "863" program [1] Revenue Sources - The main revenue sources during the reporting period include four self-commercialized products and two introduced products: - SINOGEN (Interferon α1b injection) - EPOSINO (Erythropoietin injection) - WHITE-C (Granulocyte colony-stimulating factor injection) - CLOBICO (Clostridium butyricum live bacteria powder/capsule) - Apexelsin (Paclitaxel injection) - Reminton (Infliximab injection) [1]

Core Viewpoint - The company, Sinovac Biotech Ltd., has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Jinshi International as its sole sponsor. The company is recognized as one of the earliest biopharmaceutical enterprises in China, focusing on the research, production, and commercialization of recombinant proteins, antibodies, and targeted delivery therapies [1]. Group 1 - Sinovac Biotech is an innovation-driven and internationally developed biopharmaceutical company [1]. - The company is one of the first biopharmaceutical enterprises established in China and is a key industrialization base for the national "863" program [1]. - The main revenue sources during the reporting period include four self-commercialized products and two introduced products [1]. Group 2 - The self-commercialized products include SINOGEN (human interferon α1b injection), EPOSINO (human erythropoietin injection), WHITE-C (human granulocyte colony-stimulating factor injection), and CLOBICO (Clostridium butyricum live bacteria powder/capsule) [1]. - The introduced products are Apexelsin (paclitaxel injection) and Reminton (infliximab injection) [1].

Core Viewpoint - Sinovac Biotech Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities International as the sole sponsor, highlighting its focus on innovative biopharmaceuticals and international development [1]. Group 1: Company Overview - Sinovac Biotech is an innovative and internationally developed biopharmaceutical company, specializing in the research, production, and commercialization of recombinant proteins, antibodies, and targeted delivery therapies [1]. - The company is one of the earliest established biopharmaceutical enterprises in China and is recognized as one of the first industrialization bases under the national "863" program [1]. Group 2: Revenue Sources - During the historical performance period, Sinovac Biotech's primary revenue sources include four self-commercialized products and two introduced products, which are: - SINOGEN (Interferon α1b injection) - EPOSINO (Erythropoietin injection) - WHITE-C (Granulocyte colony-stimulating factor injection) - CLOBICO (Clostridium butyricum live bacteria powder/capsule) - Apexelsin (Paclitaxel injection) - Reminton (Infliximab injection) [1].

Core Viewpoint - Sinovac Biotech Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities International as the exclusive sponsor [1] Company Summary - Sinovac Biotech Ltd. is seeking to go public on the Hong Kong Stock Exchange [1] - The exclusive sponsor for this listing is CITIC Securities International [1]

Core Viewpoint - The company has submitted an application for the issuance of H-shares and listing on the Hong Kong Stock Exchange on November 6, 2025, indicating a strategic move to access international capital markets [1] Group 1 - The application materials submitted are in draft form and may be updated or revised as necessary [1] - The issuance, if implemented, will be limited to eligible foreign investors and qualified domestic investors who are authorized to conduct overseas securities investments according to Chinese laws and regulations [1]

Core Viewpoint - The company, Sinovac Biotech (688136.SH), has submitted an application for issuing H-shares and listing on the Hong Kong Stock Exchange on November 6, 2025 [1] Group 1 - The application materials were published on the Hong Kong Stock Exchange website on the same day [1] - The materials were prepared in accordance with the requirements of the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange [1] - The information contained in the application is a draft version and may be updated or revised [1]

Group 1 - Company: Sinovac Biotech Ltd. has submitted a listing application to the Hong Kong Stock Exchange [1]

Core Viewpoint - The stock of Kexing Pharmaceutical has experienced a decline of 5.09%, currently trading at 38.38 CNY per share, with a total market capitalization of 7.724 billion CNY [1] Company Overview - Kexing Biological Pharmaceutical Co., Ltd. is located in Jinan, Shandong Province, and was established on August 22, 1997. The company went public on December 14, 2020. Its main business involves the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations [1] - The revenue composition of the company is primarily from pharmaceutical products, accounting for 97.38%, while other sources contribute 2.62% [1] Fund Holdings - According to data, one fund under Southern Fund has a significant holding in Kexing Pharmaceutical. The Southern All-Weather Strategy Mixed (FOF) A (005215) held 120,000 shares in the third quarter, representing 0.6% of the fund's net value, making it the third-largest holding [2] - The estimated floating loss for the fund today is approximately 247,200 CNY [2] Fund Performance - The Southern All-Weather Strategy Mixed (FOF) A (005215) was established on October 19, 2017, with a current scale of 641 million CNY. Year-to-date, it has achieved a return of 7.41%, ranking 260 out of 342 in its category. Over the past year, the return is 9.2%, ranking 237 out of 324, and since inception, the return is 48.9% [2] Fund Management - The fund is managed by Xia Yingying and Li Wenliang. Xia has a tenure of 7 years and 362 days, with a total asset scale of 1.176 billion CNY and a best return of 64.43% during her tenure. Li has a tenure of 7 years and 244 days, managing assets totaling 1.843 billion CNY, with a best return of 47.63% [3]

格隆汇11月3日丨科兴制药(688136.SH)公布，截至2025年10月31日，公司通过上海证券交易所交易系统 以集中竞价交易方式已累计回购公司股份131.93万股，占公司目前总股本比例为0.66%，回购成交的最 高价为43.50元/股，最低价为23.14元/股，支付的资金总额为人民币4,924.18万元（不含交易佣金等费 用）。 ...